COMMUNIQUÉS West-GlobeNewswire

Streamline Health® Improves Liquidity Position and Appoints New Directors
07/02/2024
Streamline expects $4.5 million of additional liquidity will enable achievement of previously announced adjusted EBITDA breakeven of $15.5 million of installed SaaS ARR during the second half of fiscal 2024 Expanded [...]
Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
07/02/2024
SUNNYVALE, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results [...]
STERIS Announces Financial Results for Fiscal 2024 Third Quarter
07/02/2024
Third quarter revenue increases 15% as reported; 10% constant currency organic As reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22 Fiscal 2024 outlook updated DUBLIN [...]
Cytek Biosciences to Participate in Upcoming Investor Conferences
07/02/2024
FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]
LifeStance to Host Fourth Quarter and Full Year 2023 Earnings Conference Call on February 28, 2024
07/02/2024
SCOTTSDALE, Ariz., Feb. 07, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its fourth quarter and full year 2023 [...]
Treace to Report Fourth Quarter and Full-Year 2023 Financial Results
07/02/2024
Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ET PONTE VEDRA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical [...]
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
07/02/2024
FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the fourth quarter and full year [...]
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
07/02/2024
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024
07/02/2024
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report [...]
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update
07/02/2024
- First quarter fiscal 2024 revenue up 10.3% to $135.5 million - First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million - Shift to a renewed focus on sales and marketing [...]
Neurona Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Lifesciences Conference
07/02/2024
SAN FRANCISCO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today [...]
Sana Biotechnology Announces Proposed Public Offering of Common Stock
07/02/2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten [...]
23andMe Reports Third Quarter Fiscal 2024 Financial Results
07/02/2024
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 [...]
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
07/02/2024
Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024 TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4 2024 Total Q4 revenue of [...]
ONWARD® MEDICAL ANNOUNCES PRESENTATION AT BIOCAPITAL EUROPE
07/02/2024
CEO Dave Marver will present on the Company’s use of brain-computer interface technology and progress toward planned commercialization of ARC-EX® later this year EINDHOVEN, the Netherlands, Feb. 07, 2024 (GLOBE NEWSWIRE [...]
ALK and McMaster researchers discover new cell that remembers allergies
07/02/2024
Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abelló A/S have made a ground-breaking discovery: a new cell that remembers allergies. The discovery gives scientists and researchers a [...]
Kno2 Achieves HITRUST Risk-Based, Two-Year Certification for Communication Platform, Kno2fy
07/02/2024
Kno2, in collaboration with ecfirst, a HITRUST Authorized External Assessor, Secures HITRUST Certification Ensuring Elevated Standards of Security and Compliance BOISE, Idaho, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kno2 has [...]
SPINEWAY : 2023 annual results
07/02/2024
Press release Ecully, February 7, 2024 – 6 p.m. SPINEWAY 2023 annual results 2023 revenue of €10.5 million (+42%) Gross margin steady at 69% Net income heavily impacted by exceptional items Implementation in 2024 of a [...]
SPINEWAY : Résultats annuels 2023
07/02/2024
Communiqué de presse Ecully, le 7 février 2024 –18h SPINEWAY Résultats annuels 2023 Chiffre d’affaires annuel de 10,5 M€ (+ 42%) Marge brute maintenue à 69% Résultat net fortement impacté par des éléments exceptionnels [...]

Pages